Klich Izabela, Fendler Wojciech, Wyka Krystyna, Młynarski Wojciech
Department of Pediatrics, Medical University of Lodz, Poland.
Pediatr Endocrinol Diabetes Metab. 2011;17(1):10-3.
Chemokines may modulate autoimmunity through a variety of mechanisms. Recent reports suggest involvement of the IP10 (CXCL10) chemokine in autoimmunity towards pancreatic β cells.
The purpose of this study was to evaluate the effects of genetic variability of IP10 and its dependence on HLA-conferred risk of diabetes.
148 children with type 1 diabetes and 105 healthy adult controls were evaluated. Both groups underwent HLA and IP10 genotyping at rs8878. This polymorphic site is a tagging SNP of a haploblock encompassing the whole 3' untranslated region of the IP10 gene.
T allele homozygosity was protective against type 1 diabetes (Odds Ratio (OR) 0.48 (95% confidence interval (95%CI) 0.23-0.99). No conditional interaction effect was observed in carriers of the T allele (T+) with high risk HLA genotypes: OR(95%CI)=0.65 (0.86-1.68) for DQ2∗T+ genotype and OR(95%CI)=1.20 (0.37-1.16) for DQ8∗T+ genotype respectively. An interaction effect promoting earlier onset of diabetes was observed in individuals with DQ8∗T+ genotypes. In these patients diabetes was diagnosed at a mean age of 5.1 (95%CI 3.3-6.8) in comparison to 9.0 (95%CI 7.6-10.4) years in patients with other genotypes (p=0.03).
Genetic variability of the IP10 gene may play a varied role depending on the inherent genetic risk of autoimmunity. IP10 (CXCL10) variability may reduce the risk of type 1 diabetes or alter its course depending on HLA background.
趋化因子可能通过多种机制调节自身免疫。最近的报告表明,IP10(CXCL10)趋化因子参与了针对胰腺β细胞的自身免疫。
本研究的目的是评估IP10基因变异的影响及其对HLA赋予的糖尿病风险的依赖性。
对148例1型糖尿病儿童和105名健康成人对照进行了评估。两组均在rs8878位点进行了HLA和IP10基因分型。该多态性位点是一个单倍体模块的标签单核苷酸多态性,该单倍体模块涵盖IP10基因的整个3'非翻译区。
T等位基因纯合性对1型糖尿病具有保护作用(优势比(OR)0.48(95%置信区间(95%CI)0.23 - 0.99))。在T等位基因(T+)携带者与高风险HLA基因型中未观察到条件性相互作用效应:DQ2∗T+基因型的OR(95%CI)=0.65(0.86 - 1.68),DQ8∗T+基因型的OR(95%CI)=1.20(0.37 - 1.16)。在DQ8∗T+基因型个体中观察到促进糖尿病更早发病的相互作用效应。在这些患者中,糖尿病的诊断平均年龄为5.1岁(95%CI 3.3 - 6.8),而其他基因型患者为9.0岁(95%CI 7.6 - 10.4)(p = 0.03)。
IP10基因的遗传变异可能根据自身免疫的固有遗传风险发挥不同作用。IP10(CXCL10)变异可能会降低1型糖尿病的风险或根据HLA背景改变其病程。